NORCROSS, Ga.--(BUSINESS WIRE)--Mölnlycke Health Care understands that Surgical Site Infections are a leading cause of HAIs and hospital readmissions. If a patient acquires an SSI, their hospital stay will be extended, on average 9.7 days, and an estimated $20,000 in increased healthcare costs1 will be incurred. Mölnlycke offers many solutions that can be included as part of a systematic preventive Surgical Site Infection bundle including:
NEW Mepilex Border Post-Op Dressings
Mölnlycke’s new Mepilex Border Post-op dressings are specifically designed for incisions and support early patient mobilization.2,3 A new unique flex-cut pad stretches in all directions, conforming to the body even as it moves. Its Safetac® technology is clinically proven to minimize dressing-related skin damage and reduce pain3,4 plus a shower-proof seal supports longer wear time and fewer dressing changes.5 Available as a standard or antimicrobial dressing, Mepilex Border Post-Op Ag contains highly soluble silver that starts inactivating pathogenic bacteria within 30 minutes. The dressing continues to inactivate 99.99% of common microbial threats for 7 days.6-8 Mölnlycke is proud to offer customers a uniquely flexible dressing that supports early patient mobility and offers higher clinician and patient satisfaction.3,9 The Mepilex® Border Post-Op line of dressings will be available through most medical products distributors in April.
Biogel
According to the Cochrane Review, double-gloving has been recognized as the most effective method for lowering the frequency of leakage, reducing the number of glove perforations by 71%.10 Glove perforation introduces risk of SSIs that can be mitigated with glove changes and double-gloving. Mölnlycke now offers thinner, synthetic surgical glove alternatives to make double-gloving a comfortable transition from single-gloving. The new Biogel® PI Micro Indicator® Underglove, when, combined with the Biogel® PI Micro overglove, creates the proprietary Biogel Puncture Indication System® that quickly alerts the user to a glove puncture or breach with a visual cue. 85% of O.R. staff who tested the product in a user evaluation preferred the new glove combination compared to their current surgical gloves.11
HIBICLENS
Trusted for over 40 years to prevent infection, HIBICLENS is a gentle 4% CHG antiseptic skin cleanser commonly used for preoperative showering in SSI reduction bundles. Our foaming dispenser, a unique feature among CHG solutions, helps make HIBICLENS easy to use and provides patients with visual evidence that encourages better coverage. With our gentle formulation, easy to use product, and library of patient education, Mölnlycke is dedicated to helping patients remain compliant with vital infection prevention protocols.
“Mölnlycke’s purpose is to advance performance in healthcare across the world, and we aspire to equip both patients and caregivers with solutions to achieve the best outcomes. This includes the prevention of Surgical Site Infections, which are a significant issue impacting patient care and increasing health care costs,” said Randy Schwartz, Vice President – Wound Care Marketing.
“Through our patient focus, expertise and advanced technologies, Mölnlycke has developed a portfolio of SSI bundle solutions for perioperative care. Everyone involved ... the patient, health care provider, the care facility and our healthcare system overall ... benefits when we are able to work together to reduce infection rates,” said Al Concemi, Vice President – Surgical Marketing.
References:
1. Ban, Kristen A. et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. Journal of the American College of Surgeons , Volume 224 , Issue 1 , 59 - 74. 2. Johansson C et al. Preventing post-operative blisters following hip and knee arthroplasty. Wounds International, 2012. 3. Bredow, J. et al. Randomized clinical trial to evaluate the performance of a flexible self-adherent absorbent dressing coated with a soft silicone layer compared to a standard wound dressing after hip, knee or spinal surgery in comparison to standard wound dressing. Poster presentation at 5th Congress of WUWHS, Florence, Italy 2016. 4. Dykes, P.J., et al. Effects of adhesive dressings on the stratum corneum of skin. J Wound Care 2001; 10: 2, 7-10. 5. Feili, F et al. Fluid Handling Properties of Antimicrobial Post-Operative Wound Dressings. Data on file. 6. Data on file. Laboratory test 20151026-005. 7. Data on file. Laboratory test 20151109-002. 8. Data on file. Laboratory test 20151110-007 9. Van Overschelde, P. et al. A randomized controlled trial comparing two wound dressings used after elective hip and knee arthroplasty, 2016. 10. Mischke C, Veerbeck JH, Saarto A, Lavoie M-C, Pahwa M, Ijaz S, Cochrane Database of Systematic Reviews 2014;(3):CD009573. 11. Data on file, MHC.
For more information, visit our website.
Notes for editors
Mölnlycke Health Care is a provider of high-quality healthcare solutions for customers, healthcare professionals and patients worldwide. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings. Our solutions provide value for money, supported by clinical and health economic evidence.
The Mölnlycke Health Care, Biogel, HIBICLENS, Mepilex, Safetac and Indicator trademarks, names and logo types are registered globally to one or more of the Mölnlycke Health Care Group of Companies. Distributed by Mölnlycke Health Care US, LLC, Norcross, Georgia 30092. © 2017 Mölnlycke Health Care AB. All rights reserved. 1-800-882- 4582.
